Navigation Links
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Date:10/12/2009

a, including M. tuberculosis, M. avium complex, and M. avium subspecies paratuberculosis, the potential etiological agent of Crohn's disease. SQ641 also has the potential to be effective on additional clinically relevant bacteria. Sequella licensed the compound library from Daiichi-Sankyo (November 2004). Daiichi-Sankyo identified the compound class and performed extensive research and preliminary preclinical development on several drug leads. Sequella has exclusive rights to the series of TL-1 inhibitors for the treatment of TB and all other indications for nearly every worldwide market.

As announced in September 2008, Sequella also received a 3-year, $2.3 Million NIH Phase 2 SBIR grant for development of SQ641 as an antibiotic for treatment of tuberculosis. Approval for funding the 2nd year of this grant, $795,701, was received in early September 2009.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About the NIH and NIAID

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
2. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
3. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
4. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
5. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
6. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
7. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
8. Sinovac Obtains Production License for H1N1 Vaccine
9. Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System
10. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
11. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Contract Research Organization ... plans to relocate into a new 41,500 ft2 facility. ... headquarters, currently located at 16825 W. 116th St. in Lenexa, ... half times the customized laboratory space, will remain in the ... company was founded more than twenty years ago. Remaining ...
(Date:4/21/2015)... 2015 AbilTo, Inc., the nation,s leading digital ... has been accepted as a presentation to be included ... place on June 5-6, 2015 in Boston, Massachusetts ... Diabetes Association, the cost of diabetes to the American ... result of increased inpatient, outpatient, and pharmacy costs, the ...
(Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... ... Position in Automated QT Studies , ... Rochester, New York (PRWEB) October 8, 2009 -- iCardiac Technologies, Inc., ... that an international pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. ...
... ... Obama , ... Ill. (Vocus) October 7, 2009 -- The IBM Blue Gene series of energy-efficient supercomputers, ... Barack Obama as a Medal of Technology and Innovation award-winner on October 7 in ...
... NEW YORK, Oct. 7 NeoStem, Inc. (NYSE Amex: ... processing and long-term storage of adult stem cells for ... Securities and Exchange Commission has declared effective its Registration ... The Registration Statement, including the joint proxy statement, is ...
Cached Biology Technology:Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 4United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 2United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 3United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 4
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... to prevailing wisdom, a new study from plant biologists at ... indeed chaperone proteins across the membranes of chloroplasts, just as ... published online in the January issue of the journal ... tasks in a living cell is to move things across ...
... This release is available in Spanish . ... to ethnic minority groups receive worse health care in the ... world,s most developed countries. This conclusion emerges from a research ... most comprehensive bibliographic review worldwide to date on health care ...
... is impacted as much or more by environmental change ... Professor Caryn Vaughn, who serves as director of the ... extinct, we don,t necessarily think of the common species ... Vaughn. "We need to be concerned about these ...
Cached Biology News:Green plant transport mystery solved 2Poorer diabetics receive worse care than other in countries with universal health coverage 2Poorer diabetics receive worse care than other in countries with universal health coverage 3Environmental change impacts Oklahoma rivers 2
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
... EnVision™ G|2 Doublestain System is a ... visualization kit. The kit is intended ... simultaneous detection of two different antigens ... compatible with suitably diluted rabbit and ...
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Biology Products: